U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671508) titled 'Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases' on June 22.
Brief Summary: This interventional study evaluated the efficacy of Naderin (sodium nucleinate) for the prophylaxis of complications during basic therapy and medical rehabilitation in patients with socially significant diseases, including malignant neoplasms, tuberculosis, and hepatitis C. The study assessed the immunocorrective effects of Naderin on hematological parameters, the incidence of infectious complications, and clinical outcomes.
A total of 75 patients (40 in the main group and 35 in the control group) were enrolled. ...